Analysis of formulary coverage and cost of biologic disease modifying anti‐rheumatic drugs in Medicare Part D
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Pharmaceutical Health Services Research"
DOI: 10.1111/jphs.12231
Abstract: Biologic disease modifying anti‐rheumatic drugs (DMARDs) are effective for the treatment of rheumatoid arthritis but also expensive. Medicare covers an important part of the cost of biologic DMARDs in the United States; however, studies examining… read more here.
Keywords: part; coverage cost; medicare part; biologic disease ... See more keywords